98%
921
2 minutes
20
Background: Device-related thrombus (DRT) after left atrial appendage occlusion is a worrisome finding with little knowledge about when to expect it and how to prevent it. This study sought to investigate correlates of DRT after left atrial appendage occlusion, its time of diagnosis, and particularly, association with postimplantation dual antiplatelet therapy duration.
Methods And Results: Consecutive patients (n=102) after left atrial appendage occlusion with AMPLATZER Cardiac Plug/Amulet (n=59) or WATCHMAN (n=43) were included in a prospective registry (October 2011-May 2016). Follow-up was done at 1.5, 3 to 6, and 12 months postimplantation. DRT was classified as early (at 1.5 month), late (at 3-6 month), or very late (at 12-month follow-up). Postimplantation dual antiplatelet therapy was recommended for 30 to 180 days and decided independently by attending physicians. Final analysis included 99 patients, 42 (42.4%) females, with median CHADS-VASc of 4.0 (interquartile range [IQR], 3.0-5.0) and median HAS-BLED score of 2.0 (IQR, 1.0-3.0). DRTs were observed in 7 (7.1%) patients: 2 (28.6%) early, 2 (28.6%) late, and 3 (42.9%) very late. When compared with patients without DRT, those with DRT presented more often with a history of prior thromboembolism (5 [71.4%] versus 28 [30.4%]; =0.04), had lower left ventricular ejection fraction (50.0 [IQR, 35.0-55.0] versus 60.0 [IQR, 55.0-66.0]; <0.01), and had greater proportion of patients with deep device implantation (6 [85.7%] versus 36 [39.1%]; =0.04) and with larger devices implanted (30.0 mm [IQR, 27.0-33.0] versus 25.0 mm [IQR, 24.0-28.0]; <0.01). Postimplantation dual antiplatelet therapy duration was not different between the 2 groups (12.4 weeks [IQR, 6.0-49.7] with DRT versus 13.0 weeks [IQR, 7.3-26.0] without DRT; =0.77).
Conclusions: In this real-world series, DRT was observed early, late, and very late after left atrial appendage occlusion. It was related to patient and procedural characteristics but not to postimplantation dual antiplatelet therapy duration.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1161/CIRCINTERVENTIONS.117.005997 | DOI Listing |
Interdiscip Cardiovasc Thorac Surg
September 2025
Department of Electrophysiology, Abbott Inc, Chicago, IL.
We report the first use of the EnSite X system for intraoperative electrophysiological mapping during a robotic hybrid ablation (ROK-AF procedure) for long-standing persistent atrial fibrillation. Epicardial ablation targets were identified, and post-ablation electrical silencing was validated. Unlike conventional systems, its orientation-independent omnipolar technology provides directional activation vectors, high-resolution electrograms, and peak frequency analysis, thereby enhancing substrate characterisation.
View Article and Find Full Text PDFAnn Noninvasive Electrocardiol
September 2025
Azrieli Faculty of Medicine Bar Ilan University, Safed, Israel.
Objective: To investigate two conditions that have been poorly investigated in the medical literature before in the context of atrial fibrillation: the coexistence and association of right or left bundle branch block and axis deviation in patients with permanent atrial fibrillation compared to the control group of healthy subjects with sinus rhythm.
Material And Methods: We conducted an analytic, retrospective observational study performed at Ziv Medical Center, Safed, Israel, collecting data from medical history records of all patients that have been diagnosed with permanent atrial fibrillation versus healthy controlled patients with normal sinus rhythm. We analyzed their ECGs in order to assess the presence of any bundle branch block and/or axis deviation.
ESC Heart Fail
September 2025
Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Atrial functional mitral regurgitation (AFMR) is an increasingly recognized subtype of mitral regurgitation, characterized by left atrial remodelling and mitral annular dilation in the absence of primary mitral valve disease or left ventricular dysfunction. Closely linked to chronic atrial fibrillation and heart failure with preserved ejection fraction, AFMR is associated with poor clinical outcomes and represents a growing therapeutic challenge. This expert opinion paper summarizes current evidence on the epidemiology, pathophysiology, diagnosis and management strategies, including medical therapy and emerging data supporting surgical and transcatheter interventions in selected patients.
View Article and Find Full Text PDFKardiologiia
September 2025
Second Affiliated Hospital of Chongqing Medical University, Department of Ultrasound Medicine.
Objective This research investigated the application of real-time, three-dimensional speckle tracking imaging (RT-3D-STI) to evaluate left atrial (LA) function in individuals suffering from hypertensive heart disease (HHD) and heart failure with preserved ejection fraction (HFpEF).Material and methods This retrospective study included 100 patients with HHD and HFpEF hospitalized from August 2023to June 2024 (HFpEF group). 100 healthy individuals undergoing physical examinations comprised the control group.
View Article and Find Full Text PDFAim Search for subclinical manifestations of cardiotoxicity in cancer patients at high and very high risk of cardiotoxicity and evaluation of the effectiveness of drug primary prevention during the antitumor treatment. Material and methods The study included 150 cancer patients with a high and very high Mayo Clinic (USA) Cardiotoxicity Risk Score. The main group consisted of 84 patients at high and very high risk of cardiotoxicity who were prescribed cardioprotective therapy, including a fixed combination of the angiotensin-converting enzyme inhibitor (ACEI) perindopril and the beta-blocker bisoprolol with trimetazidine.
View Article and Find Full Text PDF